.jpeg)
The mechanism of action of Trametinib in the treatment of lung cancer
Trametinib (Trametinib) is a drug called a MEK inhibitor. Its mechanism of action is mainly related to cell signal transduction pathways. By inhibiting the activity ofMEK protein, it blocks Signaling of the RAS/RAF/MEK/ERK pathway, it can bind to the MEK protein and prevent its ability to phosphorylate ERK, thereby inhibiting the activity of the pathway. In this way, trametinib inhibits the growth, differentiation, and metastasis of cancer cells, and promotes apoptosis (cell death). Trametinib is mainly used to treat certain types of cancer, such as advanced or metastatic BRAF V600E/K mutation-positive non-small cell lung cancer, thyroid cancer, and melanoma.
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
